Latest filings (excl ownership)
15-12G
Securities registration termination
11 Jul 22
EFFECT
Notice of effectiveness
8 Jul 22
EFFECT
Notice of effectiveness
8 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
8-K
Termination of a Material Definitive Agreement
1 Jul 22
25-NSE
Exchange delisting
1 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 22
8-K
Other Events
22 Jun 22
8-K
Other Events
1 Jun 22
DEFM14A
Proxy related to merger
16 May 22
10-Q
2022 Q1
Quarterly report
6 May 22
8-K
Sierra Oncology Reports First Quarter 2022 Results
6 May 22
PREM14A
Preliminary proxy related to merger
29 Apr 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
DFAN14A
Additional proxy materials by non-management
13 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 22
8-K
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
13 Apr 22
8-K
Departure of Directors or Certain Officers
22 Mar 22
S-8
Registration of securities for employees
10 Mar 22
10-K
2021 FY
Annual report
10 Mar 22
8-K
Sierra Oncology Reports 2021 Year End Results
10 Mar 22
8-K
Departure of Directors or Certain Officers
7 Mar 22
424B5
Prospectus supplement for primary offering
27 Jan 22
8-K
Other Events
27 Jan 22
FWP
Free writing prospectus
27 Jan 22
424B5
Prospectus supplement for primary offering
25 Jan 22
8-K
Entry into a Material Definitive Agreement
25 Jan 22
EFFECT
Notice of effectiveness
12 Nov 21
Latest ownership filings
SC 13G/A
Rock Springs Capital Management LP
14 Feb 23
SC 13G/A
Versor Investments LP
10 Feb 23
SC 13D/A
Abingworth LLP
11 Jul 22
SC 13G/A
Vivo Capital IX, LLC
5 Jul 22
4
Change in insider ownership
1 Jul 22
4
Change in insider ownership
1 Jul 22
4
Mona Ashiya
1 Jul 22
4
Gaurav Aggarwal
1 Jul 22
4
Andrew Sinclair
1 Jul 22
4
Barbara Klencke
1 Jul 22
4
Sukhi Jagpal
1 Jul 22
4
Robert Pelzer
1 Jul 22
4
Jeffrey H Cooper
1 Jul 22
4
Andrew R Allen
1 Jul 22
4
Craig A Collard
1 Jul 22
4
STEPHEN GEORGE DILLY
1 Jul 22
4
Mary Christina Thomson
1 Jul 22
4
William D. Turner
1 Jul 22
4
Kevin Norrett
1 Jul 22
4
Christy J. Oliger
1 Jul 22
4
Georgia Erbez
1 Jul 22
4
William D. Turner
17 Jun 22
4
Kevin Norrett
17 Jun 22
4
Barbara Klencke
17 Jun 22
4
Sukhi Jagpal
17 Jun 22
4
STEPHEN GEORGE DILLY
17 Jun 22
4
Mary Christina Thomson
17 Jun 22
SC 13D/A
Longitude Capital Partners III, LLC
6 May 22
4
PATRICK G ENRIGHT
29 Apr 22
SC 13G
Versor Investments LP
22 Apr 22
4
William D. Turner
7 Apr 22
4
Mary Christina Thomson
4 Apr 22
SC 13G/A
Frazier Life Sciences Public Fund, L.P.
29 Mar 22
4
William D. Turner
22 Mar 22
SC 13D/A
Abingworth LLP
21 Mar 22
4
William D. Turner
17 Mar 22
SC 13D/A
ORBIMED ADVISORS LLC
15 Mar 22
4
STEPHEN GEORGE DILLY
14 Mar 22
4
Sukhi Jagpal
14 Mar 22
4
Barbara Klencke
14 Mar 22